Related Experiment Video
Updated: Mar 3, 2026
10:19
A Murine Model of Group B Streptococcus Vaginal Colonization
Published on: November 16, 2016
15.2K
Group B Streptococcus and perinatal mortality.
1Laboratory Bacteriology Research, Department of Microbiology, Immunology and Clinical Chemistry, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
Research in Microbiology
|April 25, 2017
Summary
Neonatal infections cause one million deaths annually. This study examines how Streptococcus agalactiae (group B Streptococcus, GBS) contributes to neonatal disease and stillbirth.
Area of Science:
- Neonatal Health
- Infectious Diseases
- Microbiology
Background:
- Neonatal infections are a leading cause of mortality worldwide.
- An estimated one million neonatal deaths and one million stillbirths are attributed to infections annually.
- Streptococcus agalactiae, also known as group B Streptococcus (GBS), is a significant pathogen in this context.
Purpose of the Study:
- To elucidate the role of Streptococcus agalactiae (GBS) in neonatal infections.
- To highlight the impact of GBS on neonatal mortality and stillbirth rates.
- To provide a comprehensive overview of GBS as a cause of neonatal disease.
Main Methods:
- Literature review and synthesis of existing data on GBS.
- Analysis of epidemiological data concerning neonatal infections and stillbirths.
- Discussion of the pathogenic mechanisms of GBS in neonates.
Main Results:
- Streptococcus agalactiae (GBS) is a major contributor to neonatal sepsis and meningitis.
- GBS is implicated in a substantial proportion of infection-related stillbirths.
- The burden of GBS disease places a significant strain on global neonatal healthcare.
Conclusions:
- Streptococcus agalactiae (GBS) represents a critical threat to neonatal survival.
- Effective strategies are needed to prevent and manage GBS infections in newborns.
- Further research into GBS pathogenesis and prevention is essential for reducing neonatal mortality and stillbirths.
